nivolumab,ipilimumab
bms
['nivo', 'nivolumab', 'ipilimumab']
phs ii study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal #wcgic2023 trend for higher efficacy with dual ici, but also more toxicity we need predictive biomarkers 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology